The FDA has granted Breakthrough Therapy Designation to Chugai’s satralizumab, a treatment currently in phase 3 for the rare CNS disorders neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD).
The FDA has granted Breakthrough Therapy Designation to Chugai’s satralizumab, a treatment currently in phase 3 for the rare CNS disorders neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD).
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![Maak saaie content interessant: spelen met invalshoeken [3 tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/01/high-angle-shot-of-a-diverse-business-team-hands-p-2023-11-27-05-19-55-utc-1-80x60.jpg)